Boehringer Ingelheim’s new IPF drug accepted for EU review

Boehringer Ingelheim has announced that the European Medicines Agency has accepted its marketing authorisation application for a new idiopathic pulmonary fibrosis (IPF) therapy.

Nintedanib, a tyrosine kinase inhibitor, has been validated for review and granted accelerated assessment status by the regulatory body, demonstrating its potential to address an unmet medical need.

The application is supported by clinical trial data from two phase III studies, INPULSIS-1 and INPULSIS-2, both of which showed the drug's ability to significantly slow disease progression in patients with IPF.

Nintedanib is the first targeted treatment for IPF that has consistently demonstrated its efficacy on this metric, significantly reducing the decline in lung function with a manageable side effect profile.

Professor Klaus Dugi, chief medical officer at Boehringer Ingelheim, said: "Acceptance of our marketing authorisation application takes us one step closer to meeting this unmet need and providing a new treatment option to patients living with IPF."

This comes after the company received EU approval last month for Jardiance, a new therapy for type 2 diabetes developed in partnership with Lilly.